RT Journal Article
T1 Risk-Adapted Treatment in Clinical Stage I Testicular Seminoma: The Third Spanish Germ Cell Cancer Group Study
A1 Aparicio, Jorge
A1 Maroto, Pablo
A1 García del Muro, Xavier
A1 Guma, Josep
A1 Sánchez-Muñoz, Alfonso
A1 Margelí, Mireia
A1 Domenech, Montserrat
A1 Bastús, Romá
A1 Fernández, Antonio
A1 Lopez-Brea, Marta
A1 Terrassa, Josefa
A1 Meana, Andrés
A1 Martínez del Prado, Purificación
A1 Sastre, Javier
A1 Satrustegui, Juan J.
A1 Girones, Regina
A1 Robert, Lidia
A1 Germa, José R.
K1 Testículos - Cáncer - Tratamiento
AB PurposeTo confirm the efficacy of a risk-adapted treatment approach for patients with clinical stage Iseminoma. The aim was to reduce both the risk of relapse and the proportion of patients receivingadjuvant chemotherapy while maintaining a high cure rate.Patients and MethodsFrom 2004 to 2008, 227 patients were included after orchiectomy in a multicenter study.Eighty-four patients (37%) presented no local risk factors, 44 patients (19%) had tumors largerthan 4 cm, 25 patients (11%) had rete testis involvement, and 74 patients (33%) had both criteria.Only the latter group received two courses of adjuvant carboplatin, whereas the rest weremanaged by surveillance.ResultsAfter a median follow-up time of 34 months, 16 relapses (7%) have been documented (15 [9.8%]among patients on surveillance and one [1.4%] among those treated with carboplatin). All relapsesoccurred in retroperitoneal lymph nodes, except for one case in pelvic nodes. Median node sizewas 25 mm, and median time to recurrence was 14 months. All patients were rendereddisease-free with chemotherapy. The actuarial 3-year disease-free survival rate was 88.1% (95%CI, 82.3% to 93.9%) for patients on surveillance and 98.0% (95% CI, 94.0% to 100%) for thosetreated with adjuvant chemotherapy. Overall 3-year survival was 100%.ConclusionWith the limitations of the short follow-up duration, we confirm that a risk-adapted approach iseffective for stage I seminoma. Adjuvant carboplatin seems adequate treatment for patients with2 risk criteria, as is active surveillance for those with 0 to one risk factors. More reliable predictivefactors are needed to improve the applicability of this model.
PB Editorial Roster. ASCO publications
YR 2011
FD 2011-10
LK https://hdl.handle.net/10630/29747
UL https://hdl.handle.net/10630/29747
LA spa
NO Aparicio J, Maroto P, del Muro XG, Gumà J, Sánchez-Muñoz A, Margelí M, Doménech M, Bastús R, Fernández A, López-Brea M, Terrassa J, Meana A, del Prado PM, Sastre J, Satrústegui JJ, Gironés R, Robert L, Germà JR. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol. 2011 Dec 10;29(35):4677-81. doi: 10.1200/JCO.2011.36.0503. Epub 2011 Oct 31. PMID: 22042940.
NO Este artículo ha sido publicado en Journal of Clinical OncologyEl archivo que deposito es el posprint que me ha enviado la editorial, lo cual aclaro para para que quede constancia y no haya confusión al respectoEsta versión tiene Licencia Creative Commons CC-BY-NC-ND
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 19 ene 2026